Related Experiment Video
Updated: Jan 10, 2026
05:54
Stereo-Electro-Encephalo-Graphy SEEG With Robotic Assistance in the Presurgical Evaluation of Medical Refractory Epilepsy: A Technical Note
Published on: June 13, 2016
17.9K
Artificial intelligence for epilepsy decision support
Itai Loushy1, Michael R Sperling1
1Department of Neurology, Jefferson Comprehensive Epilepsy Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Epilepsia
|November 21, 2025
Summary
Artificial intelligence (AI) offers significant potential in epilepsy care by improving diagnostic accuracy and treatment efficiency. Responsible adoption requires addressing ethical concerns and validating AI tools in real-world clinical settings.
Area of Science:
- Neurology
- Medical Informatics
- Artificial Intelligence
Background:
- Epilepsy diagnosis and treatment present challenges due to uncertainty and variability.
- Artificial intelligence (AI) is emerging as a tool to address these complexities.
- Current applications span diagnostics, treatment prediction, and workflow optimization.
Purpose of the Study:
- To review the current and potential applications of AI in epilepsy management.
- To highlight opportunities for AI in improving efficiency and diagnostic accuracy.
- To discuss challenges and ethical considerations for responsible AI adoption.
Main Methods:
- Review of AI applications in key epilepsy domains: history-taking, electronic records, EEG, MRI, and multimodal data.
- Examination of AI's role in predicting seizure recurrence, drug resistance, and surgical candidacy.
- Analysis of challenges in outcome measurement for epilepsy therapies and AI integration.
Main Results:
- AI can enhance efficiency through task automation and improve diagnostic accuracy.
- AI offers potential in predicting treatment response and surgical outcomes.
- Ethical considerations including bias, transparency, and privacy are critical for AI implementation.
Conclusions:
- AI shows promise as a decision-support tool to augment clinical judgment in epilepsy.
- Validation in diverse real-world settings and clinician partnership are essential for responsible AI adoption.
- Addressing ethical concerns is paramount for the successful integration of AI in epilepsy care.
Related Concept Videos
01:24Epilepsy and Seizures: Overview
1.1K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
01:13Seizures: Classification
1.3K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.3K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
799
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
799
01:14Antiepileptic Drugs: Glutamate Antagonists
865
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
865